Data demonstrate efficacy of more flexible dose of regorafenib to relieve side-effects in mCRC patients

Some of the adverse events related to the use of regorafenib often limits its use in clinical practice. A study suggests the usefulness of a more flexible dosing, which improves patients’ quality of life without jeopardizing efficacy.

From https://www.sciencedaily.com/releases/2019/07/190706123457.htm

from
https://healthnews010.wordpress.com/2019/07/07/data-demonstrate-efficacy-of-more-flexible-dose-of-regorafenib-to-relieve-side-effects-in-mcrc-patients/

From https://jamesjohnson10.blogspot.com/2019/07/data-demonstrate-efficacy-of-more.html

from
https://jamesjohnson10.wordpress.com/2019/07/07/data-demonstrate-efficacy-of-more-flexible-dose-of-regorafenib-to-relieve-side-effects-in-mcrc-patients/

From https://judywright2.blogspot.com/2019/07/data-demonstrate-efficacy-of-more.html

from
https://judywright2.wordpress.com/2019/07/07/data-demonstrate-efficacy-of-more-flexible-dose-of-regorafenib-to-relieve-side-effects-in-mcrc-patients/